Full-Time

Software Engineer 1

Posted on 4/14/2026

Deadline 4/18/26
LabCorp

LabCorp

10,001+ employees

Global life sciences R&D services

No salary listed

No H1B Sponsorship

Hartford, CT, USA

In Person

Bachelor's, Associate's

Category
Software Engineering (2)
,
Required Skills
Rust
Python
Git
Java
C/C++

Get referred to LabCorp

See people who can refer or advise you

Requirements
  • Bachelor’s degree in Engineering, Computer Science, Information Technology, or an Associate’s degree with 2 or more years of experience in robotics, or a high school diploma with 4 or more years of experience in robotics.
  • 1 or more years of experience through internships, co‑op programs, or entry‑level roles supporting software development in manufacturing or automation environments.
  • 1 or more years of experience using at least one programming language such as Java, C/C++, Python, or Rust.
  • 1 or more years of experience with object‑oriented programming principles and basic software architecture concepts.
  • 1 or more years of experience using integrated development environments such as Eclipse or Visual Studio Code and version control tools such as Git.
Responsibilities
  • Develop and support embedded and application‑level software for laboratory robotic systems.
  • Contribute to the design and implementation of robotic control software and user‑interface applications under guidance from senior engineers.
  • Assist in the development of core tools and utilities that simplify robotic automation programming.
  • Partner with Manufacturing Engineering to create bring‑up, testing, and diagnostic software for production automation equipment.
  • Collaborate with Customer Care teams to diagnose and troubleshoot real‑world field service issues.
  • Adhere to ISO 13485 quality standards to support compliant medical device software development practices.
  • Stay current with industry trends and best practices in robotics, automation, and software development.
  • Participate in code reviews, technical discussions, and team collaboration sessions.
  • Support continuous improvement initiatives to enhance software quality and development processes.
Desired Qualifications
  • 1 or more years of experience with a Robotics internship.

Labcorp provides end-to-end R&D services for life sciences and agricultural clients, including crop protection, with testing and regulatory support. It runs physicochemical analyses, safety assessments, and inhalation toxicology studies using specialized labs to evaluate inhaled substances. It differentiates itself with a global footprint and an integrated set of services across the product lifecycle, including regulatory submissions. Its goal is to help clients bring safe, effective products to market efficiently by applying rigorous science and scalable testing.

Company Size

10,001+

Company Stage

IPO

Headquarters

Burlington, Vermont

Founded

1976

Get referred to LabCorp

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 30, 2026 revenue rose 5.8% to $3.73 billion, with margins up 70 basis points.
  • Labcorp raised 2026 guidance to 5.4%-6.3% revenue growth and $18.10-$18.55 adjusted EPS.
  • August 2026 PTEN and melanoma launches deepen precision-oncology revenue across its U.S. network.

What critics are saying

  • Ravgen’s $272.5 million patent verdict still hangs over prenatal testing economics.
  • Quest Diagnostics keeps winning share with 2026 forecast raises and stronger routine-testing demand.
  • The Bedford closure and 94 layoffs show site rationalization pressure in Massachusetts through January 2027.

What makes LabCorp unique

  • Labcorp pairs diagnostics with drug-development services across 2,200 patient service centers.
  • August 10, 2026 FDA approval for PGDx elio tissue complete CDx expands companion diagnostics.
  • Labcorp combines oncology, women’s health, autoimmune, and consumer genetics through Marker and OnDemand.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

Unlimited Paid Time Off

Tuition Reimbursement

Employee Stock Purchase Plan

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 12th, 2026
Labcorp CEO sells $1.5M in shares as stock delivers 21% annual return

Labcorp CEO Adam Schechter sold 4,669 shares of the company for approximately $1.5 million on 11 August 2026, according to an SEC filing. The transaction was executed under a Rule 10b5-1 plan, which allows insiders to sell shares on a predetermined schedule whilst complying with insider trading regulations. The sale represented approximately 4% of Schechter's direct holdings. He continues to hold 102,565 shares valued at $33 million as of the transaction date. Labcorp shares achieved a 21% total return over the 12 months ending on the transaction date. Labcorp Holdings provides diagnostic laboratory services and drug development support. The company has 71,000 employees and a market capitalisation of $26.4 billion.

Yahoo Finance
Aug 10th, 2026
Labcorp stock trades at premium despite stronger growth and improved margins

Labcorp Holdings is showing improved growth in the second half of 2026, with stronger revenue, wider margins, and raised full-year guidance. Specialty testing in oncology, women's health, and autoimmune disease delivered double-digit revenue growth in the first half. The company's 2026 revenues are expected to grow 5.6% year over year. Second-quarter adjusted operating margin expanded 70 basis points year over year to 15.8%. Diagnostics margin rose 50 basis points to 18%, whilst Biopharma Laboratory Services margin increased 130 basis points to 17%. The gains came from organic growth, operating efficiencies, and technology initiatives including automation and artificial intelligence. However, the stock now trades at 16.7 times forward 12-month earnings, above both its five-year median of 14.4 times and its industry multiple of 16.2 times, leaving limited room for execution errors.

PR Newswire
Aug 10th, 2026
Labcorp gains FDA approval for melanoma companion diagnostic test

Labcorp announced that the US Food and Drug Administration has approved its PGDx elio tissue complete CDx as a companion diagnostic for advanced melanoma patients. The test identifies patients with certain BRAF variants who may benefit from FDA-approved BRAF inhibitors and BRAF/MEK inhibitor combination therapies. Melanoma is the deadliest form of skin cancer, with a five-year survival rate of just 16% for stage IV patients. Targeted therapies offer an important treatment option for patients whose tumours have BRAF alterations. The companion diagnostic is approved for use by qualified healthcare professionals across hospitals and clinical laboratories. As a kit-based solution, it can be implemented directly within hospitals and health systems, expanding testing access whilst enabling organisations to retain samples for future clinical research.

Taylor & Francis
Aug 6th, 2026
Labcorp expands access to FDA-approved PTEN diagnostic test for prostate cancer.

Labcorp expands access to FDA-approved PTEN diagnostic test for prostate cancer. 6 Aug 2026 Labcorp (NC, USA) has announced US-wide availability of the VENTANA PTEN (SP218) RxDx Assay, Roche's immunohistochemistry (IHC) companion diagnostic test for prostate cancer, marking a significant step forward in precision oncology. With the American Cancer Society (GA, USA) estimating >330,000 new cases of prostate cancer in 2026 in the United States, there is an urgent need for advanced diagnostic tools in this area. In recent years, focus has shifted to the tumor suppressor protein PTEN (phosphatase and tensin homolog on chromosome 10), which has been shown to play a critical role in regulating cell growth. Loss of PTEN protein expression has been linked with more aggressive disease progression and reduced benefit from current standard-of-care therapies in prostate cancer patients. You may also be interested in: The VENTANA PTEN (SP218) RxDx Assay is the first IHC companion diagnostic test approved by the US FDA for determining PTEN protein loss in the tumors of patients with prostate adenocarcinoma. The assay equips clinicians with critical biomarker information to help steer treatment decisions and support personalized patient care. "Biomarker testing is essential to advancing precision oncology and helping connect patients with the therapies most appropriate for their disease," commented Shakti Ramkissoon, Vice President and Medical Lead for oncology at Labcorp. "The launch of the VENTANA PTEN (SP218) RxDx Assay underscores how Labcorp is expanding access to innovative companion diagnostics and delivering the timely insights physicians need to make personalized treatment decisions." The assay facilitates the identification of patients who could be eligible for treatment with TRUQAP(R)(capivasertib), developed by AstraZeneca (Cambridge, UK). Now available through Labcorp's network of US-based laboratories, the assay complements the company's comprehensive portfolio of testing services supporting precision oncology care.

PR Newswire
Aug 4th, 2026
Labcorp launches FDA-approved PTEN test for prostate cancer treatment eligibility

Labcorp has launched nationwide availability of Roche's VENTANA PTEN (SP218) RxDx Assay, the first FDA-approved immunohistochemistry companion diagnostic test for prostate cancer. The assay detects PTEN protein loss in prostate adenocarcinoma tumors, helping identify patients eligible for treatment with AstraZeneca's TRUQAP (capivasertib) in combination with abiraterone acetate and prednisone. PTEN is a tumor suppressor protein that regulates cell growth. Loss of PTEN protein expression has been associated with more aggressive disease progression and reduced benefit from standard therapies. Labcorp participated in Roche's early access programme to support Day 1 laboratory readiness for the assay. The test is now available through Labcorp's national network of laboratories and complements the company's comprehensive portfolio of genomic and molecular testing services supporting precision oncology care.

INACTIVE